Corporate and Business Update; Viropro Committed to Increase Its Visibility.MONTREAL -- Viropro Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB: VPRO An x86 chip platform from Intel that supports hardware-based remote systems management. It comprises a Core 2 Duo CPU and a chipset that features Intel's Active Management Technology (AMT). ) ("Viropro" or the "company") today provides a corporate update to the financial community and to its shareholders. The recent reinforcement of Viropro's management team will allow the company to focus and to set short and mid-term priorities to maximize shareholders' value. Business development On June 15, 2006, the company announced the signature of a binding Memorandum of Understanding A Memorandum of Understanding (MoU) is a legal document describing a bilateral or multilateral agreement between parties. It expresses a convergence of will between the parties, indicating an intended common line of action and may not imply a legal commitment. (MOU (Minutes Of Usage) A metric used to compute billing and/or statistics for telephone calls or other network use. ) with Biochallenge, a Tunisia-based privately held pharmaceutical company, for the development and the production of several therapeutic proteins, with potential revenues estimated at US$27 Million. The final contractual agreement is expected in the next following months. Letters of Intent (LOI LOI Letter of Indemnity (international trade and carriage business) LOI Letter Of Intent LOI Loss On Ignition LOI Letter of Inquiry LOI Lack Of Information LOI Lack of Interest LOI Letter of Invitation LOI List Of Items ) are in progress with 5 other partners and the company is expecting to sign 2 to 3 LOI in the next coming quarters. Scientific advisors and board members Appointments of well renowned individuals for both the bio-generic and vaccine segment are expected gradually within the next quarters. Theravax Inc Theravax Inc, a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Viropro, has been created to develop therapeutic vaccines therapeutic vaccine Immunology A vaccine–eg, Salk's Remune™ intended to treat a viral infection by stimulating the immune system. See Vaccine therapy. for treatment of patients with cancer or chronic viral infections such as AIDS, chronic hepatitis Chronic hepatitis Long lasting inflammation of the liver due to viruses or other causes. Mentioned in: Tube Compression of the Esophagus and Stomach chronic hepatitis and cancer. Management is negotiating with a partner to acquire a platform technology to develop and market its first product, an AIDS therapeutic vaccine to be tested in Canada and Brazil in patients with chronic HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. infections. The technology could allow Theravax to become a world leader in the field of AIDS vaccines. The company is pursuing various strategies to increase its visibility on the market, thus ensuring maximization of shareholders value. Here are some of them: --To increase our US exposure --To redefine the way the company is executing its public relations public relations, activities and policies used to create public interest in a person, idea, product, institution, or business establishment. By its nature, public relations is devoted to serving particular interests by presenting them to the public in the most --To add financial resources to promote the company (explain the story) within the financial community --To increase our presence in various media (newspapers, publications, TV, tribunes, forums) --To present at scientific symposiums/shows --To organize conference calls for investors --To be listed on a Canadian and/or a European Exchange --To do quarterly business updates Most of these strategies should progressively take place within the next quarters. Corporate exposure/image Viropro initiated an in depth review of its web site to facilitate the understanding of the business. The following issues will be addressed, added, and updated: operational segments; products; agreements in progress; new logo and new corporate image; fact sheets for both segments; corporate presentation; upcoming events section; scientific papers/articles; frequent questions and answers and definition of terms used. User access to the web site should also be quicker. Some changes have already been "posted" on the actual site and the revamping is expected to be completed by the next quarter. About Viropro Inc. Viropro Inc. conducts operations mainly through its subsidiary Viropro International Inc. whose head office is located in Montreal, Canada. Viropro is a rapidly expanding biopharmaceutical company specializing in the commercialization of transfer technology of its expertise in the industrial production of biogeneric therapeutic proteins and the development of curative curative /cur·a·tive/ (kur´ah-tiv) tending to overcome disease and promote recovery. cu·ra·tive adj. 1. Serving or tending to cure. 2. vaccines for the treatment of various diseases including cancer, diabetes, hepatitis, muscle and joint maladies, multiple sclerosis and AIDS. The company's principal objective is to bring about the transfer of technology to pharmaceutical companies in those parts of the world where demand for biopharmaceutical products has not been met, such as in South America South America, fourth largest continent (1991 est. pop. 299,150,000), c.6,880,000 sq mi (17,819,000 sq km), the southern of the two continents of the Western Hemisphere. , Asia and Africa. To expand its range of expertise, Viropro has concluded strategic alliances with various scientific and business partners renowned in national and international spheres. Viropro's business model rests on a strategy aimed at generating recurrent short- and long-term revenues, all while augmenting the value of assets and profits of its shareholders. For more information on Viropro Inc, please visit our website on www.viropro.com Viropro Inc.'s Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements". Forward-looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion